Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) closed its acquisition of PharmaCann Penn, LLC for an aggregate consideration of $50 million. The deal secures nine operational retail medical marijuana dispensaries in Pennsylvania, reinforcing Cresco’s market leadership in the second-largest US medical cannabis market.

The transaction positions Cresco as the number one retailer providing medical marijuana to patients across Pennsylvania. Combined with its existing position as the state’s leading wholesaler, the company aims to leverage scale and vertical integration to drive competitive advantages.

Transaction Structure

The purchase price of $50,000,000 was satisfied through a combination of cash and a seller note. The deal was executed on a cash-free, debt-free basis with a mutually agreed-upon normalized target level of working capital.

Charlie Bachtell, CEO of Cresco Labs, stated that the company is focused on deploying capital into opportunities that strengthen its competitive position and generate attractive long-term returns. He noted that pairing additional retail doors with scaled cultivation and wholesale operations reinforces Cresco’s role as a consolidator in core markets.

What the Numbers Show

The acquisition targets a market generating more than $1.1 billion in annual sales last year, according to Hoodie Analytics. By acquiring nine doors for $50 million, Cresco is paying approximately $5.56 million per dispensary. This entry cost allows the company to immediately capture revenue in a high-volume jurisdiction while consolidating its dual dominance in both wholesale distribution and retail sales within Pennsylvania.

Strategic Outlook

Cresco expects the transaction to be immediately accretive to revenue, margins, and cash flow. The company plans to leverage its existing infrastructure to integrate the new locations efficiently. This move aligns with Cresco’s broader mission to normalize the medical marijuana industry through a consumer packaged goods approach to brand building and retail experience.

Cresco Labs Inc. will report its financial results for the quarter ended June 30, 2026, on Thursday, August 6, 2026, before the market opens. The company, a leader in branded cannabis products and operator of Sunnyside dispensaries, will provide key business highlights during the announcement.

Conference Call Details

Cresco Labs will host a conference call and webcast to discuss its Q2FY26 financial results. Investors can access the live event to review performance metrics and strategic updates.

Archived access to the webcast will be available for one year on the Cresco Labs investor relations website.

About Cresco Labs Inc.

Cresco Labs focuses on normalizing and professionalizing the cannabis industry through a CPG approach to building national brands and a customer-focused retail experience. The company operates cultivation, production, and branded product distribution, leveraging its scale to grow brands such as Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s, and Remedi. It also operates dispensaries under the Sunnyside brand, emphasizing patient and consumer trust, education, and convenience.